Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

de Sanjose, S., Quint, W. G., Alemany, L., Geraets, D. T., Klaustermeier, J. E., Lloveras, B., Tous, S., Felix, A., Bravo, L. E., Shin, H.-R., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70230-8 · Cited by 2,728

Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis

de Martel, C., Georges, D., Bray, F., Ferlay, J., & Clifford, G. M. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(19)30488-7 · Cited by 2,475

Against which human papillomavirus types shall we vaccinate and screen? the international perspective

Muñóz, N., Bosch, F. X., Castellsagué, X., Díaz, M., de Sanjosé, S., Hammouda, D., Shah, K. V., & Meijer, C. J. L. M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20244 · Cited by 1,095

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

Li, N., Franceschi, S., Howell‐Jones, R., Snijders, P. J. F., & Clifford, G. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25396 · Cited by 1,067

PROPORTION OF DISEASE CAUSED OR PREVENTED BY A GIVEN EXPOSURE, TRAIT OR INTERVENTION1

MIETTINEN, O. S. (1974) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a121617 · Cited by 1,036

Human papillomavirus types in 115,789 HPV‐positive women: A meta‐analysis from cervical infection to cancer

Guan, P., Howell‐Jones, R., Li, N., Bruni, L., de Sanjosé, S., Franceschi, S., & Clifford, G. M. (2012) · International Journal of Cancer · doi:10.1002/ijc.27485 · Cited by 927

Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline

SCHIFFMAN, M. H., Clifford, G. M., & Buonaguro, L. (2009) · Infectious Agents and Cancer · doi:10.1186/1750-9378-4-8 · Cited by 463

One virus, one lesion—individual components of CIN lesions contain a specific HPV type

Quint, W. G. V., Jenkins, D., Molijn, A. C., Struijk, L., van de Sandt, M. M., Doorbar, J., Mols, J., HOOF, C. V., Hardt, K., Struyf, F., et al. (2011) · The Journal of Pathology · doi:10.1002/path.3970 · Cited by 196

Carcinogenicity of Human Papillomavirus (HPV) Types in HIV-Positive Women: A Meta-Analysis From HPV Infection to Cervical Cancer

Clifford, G. M., Tully, S., & Franceschi, S. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix135 · Cited by 196

Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants

Wentzensen, N., SCHIFFMAN, M. H., Dunn, T., Zuna, R. E., Gold, M. A., Allen, R. A., Zhang, R., Sherman, M. E., Wacholder, S., Walker, J. L., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24528 · Cited by 186

Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use

Zhang, Y., Qiu, K., Ren, J., Zhao, Y. Q., & Cheng, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02083-w · Cited by 125

Global HPV vaccination programs and coverage rates: a systematic review

Jingjing, H., Zhang, L., Chen, Y., Zhang, Y., Wang, L., Cai, R., Li, M., Dai, Y., Dang, L., Chen, H., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103290 · Cited by 118

Human papilloma virus (HPV) mediated cancers: an insightful update

Baba, S. K., Alblooshi, S. S. E., Yaqoob, R., Behl, S., Saleem, M. A., Rakha, E. A., Malik, F. A., Singh, M. K., Macha, M. A., Akhtar, K., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06470-x · Cited by 90

Applying Results of Extended Genotyping to Management of Positive Cervicovaginal Human Papillomavirus Test Results: Enduring Guidelines

Massad, L. S., Clarke, M. A., Perkins, R. B., García, F., Chelmow, D. P., Cheung, L. C., Darragh, T. M., Egemen, D., Lorey, T. S., Nayar, R., et al. (2025) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000865 · Cited by 71

Human papillomavirus-based cervical screening and long-term cervical cancer risk: a randomised health-care policy trial in Sweden

Wang, J., Elfström, K. M., & Dillner, J. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00218-4 · Cited by 63

Cancer of the cervix uteri: 2025 update

Bhatla, N., Aoki, D., Sharma, D. N., & Sankaranarayanan, R. (2025) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70277 · Cited by 58

Noninferiority of One HPV Vaccine Dose to Two Doses

Kreimer, A. R., Porras, C., Liu, D., Hildesheim, A., Carvajal, L. J., Ocampo, R., Romero, B., Gail, M. H., Cortés, B., Sierra, M. S., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2506765 · Cited by 54

Advances and prospects of precision nanomedicine in personalized tumor theranostics

Mao, Y., Xie, J., Yang, F., Luo, Y., Du, J., & Xiang, H. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1514399 · Cited by 38

Population-Based Age-Period-Cohort Analysis of Declining Human Papillomavirus Prevalence

Gray, P. G., Wang, J., Kleppe, S. N., Elfström, M. K., & Dillner, J. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf032 · Cited by 32

A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination

Malvi, S. G., Esmy, P. O., Muwonge, R., Joshi, S., Poli, U. R., Lucas, E., Verma, Y., Lucksom, P. G., Shah, A., Patel, B. M., et al. (2024) · JNCI Monographs · doi:10.1093/jncimonographs/lgae042 · Cited by 30

Global, regional, and national burden of cervical cancer in 2022 and projections to 2050: a population-based analysis of GLOBOCAN

Son, Y., Hong, S., Jang, W., Kim, S., Lee, H., Lee, S., Kang, J., Smith, L., & Yon, D. K. (2025) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.102751 · Cited by 28

Evolution and future of cervical cancer screening: from cytology to primary HPV testing and the impact of vaccination

El‐Zein, M., & Franco, E. L. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2486653 · Cited by 19

Development, validation, and clinical application of a machine learning model for risk stratification and management of cervical cancer screening based on full-genotyping hrHPV test (SMART-HPV): a modelling study

Dong, B., Lü, Z., Yang, T., Wang, J., Zhang, Y., Tuo, X., Wang, J., Lin, S., Cai, H., Huan, C., et al. (2025) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2025.101480 · Cited by 20

Initial evaluation of a new cervical screening strategy combining human papillomavirus genotyping and automated visual evaluation: the Human Papillomavirus–Automated Visual Evaluation Consortium

Befano, B., Kalpathy–Cramer, J., Egemen, D., Inturrisi, F., Jerónimo, J., Rodríguez, A. C., Campos, N. G., Cremer, M., Ribeiro, A. K. D. C., Ajenifuja, K. O., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf054 · Cited by 17

A hybrid approach for cervical cancer detection: Combining D-CNN, transfer learning, and ensemble models

Hanzala, A., Akter, T., & Rahman, M. S. (2025) · Array · doi:10.1016/j.array.2025.100434 · Cited by 19

Enhancing Cervical Cancer Screening: New Diagnostic Methodologies, Triage, and Risk Stratification in Prevention and Treatment

Kamzayeva, N., Bapayeva, G., Terzić, M., Primbetov, B., Imankulova, B., Kim, Y., Sultanova, A., Kongrtay, K., Kadroldinova, N., & Ukybassova, T. (2025) · Life · doi:10.3390/life15030367 · Cited by 19

Impact of Smoking on Cervical Histopathological Changes in High-Risk HPV-Positive Women: A Matched Case–Control Study

Kayar, İ., Göç, G., Çetin, F., & Birge, Ö. (2025) · Medicina · doi:10.3390/medicina61020235 · Cited by 15

Population-Level Effectiveness and Herd Protection 17 Years After HPV Vaccine Introduction

DeSieghardt, A., Ding, L., Ermel, A. C., Franco, E. L., Dagnall, C. L., Brown, D. R., Yao, S., & Kahn, J. A. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.3568 · Cited by 14

The Epithelial Immune Response to Human Papillomavirus Infection

Roy-Biswas, S., & Hibma, M. H. (2025) · Pathogens · doi:10.3390/pathogens14050464 · Cited by 17

Global trends and future projections of cervical cancer burden: an integrated analysis of GBD 2021, UN population and WHO HPV vaccination data

Shao, D., Wu, P., Jiang, H., & Wang, Z. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1702186 · Cited by 13

Cancer burden and control in China: landscape, trends and challenges

Xia, C., Li, H., Chen, W., & Chen, W. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01165-8 · Cited by 18

The socioeconomic burden of cervical cancer and its implications for strategies required to achieve the WHO elimination targets

Brotherton, J. M. L., Vajdic, C. M., & Nightingale, C. E. (2025) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2025.2451732 · Cited by 14

Cancer Development and Progression Through a Vicious Cycle of DNA Damage and Inflammation

Kawanishi, S., Wang, G., Ma, N., & Murata, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073352 · Cited by 12

Global status of HPV vaccination two decades in: effective, safe and preventing cancer

Brotherton, J. M. L., LaMontagne, D. S., & Bloem, P. N. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2609869 · Cited by 12

Sexually transmitted human papillomavirus and related sequelae

Hanft, W., Karita, H. C. S., Khorsandi, N., Vohra, P., & Plotzker, R. E. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00085-23 · Cited by 15

Reflections Regarding Validation of New HPV Tests With Reduced HPV Genotypes: Report From an IARC Expert Consultation

Ramírez, A. T., Clifford, G. M., Dillner, J., Kuhn, L., Arbyn, M., Bhatla, N., Wentzensen, N., Sasieni, P. D., Abraham, P., Rol, M. L., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70310 · Cited by 10

The effect of bivalent HPV vaccination against invasive cervical cancer and cervical intraepithelial neoplasia grade 3 (CIN3+) in the Netherlands: a population-based linkage study

Middeldorp, M., Brouwer, J. G. M., Duijster, J. W., Knol, M. J., van Kemenade, F. J., Siebers, A. G., Berkhof, J. H., & de Melker, H. E. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101327 · Cited by 11

Amplification-free CRISPR/Cas12a biosensor integrating AuNPs-mediated surface plasmon resonance for human papillomavirus detection and genotyping

Deng, Z., Mao, X., Yang, Y., Wu, G., Meng, H., Hou, J., Yu, X., Zhou, W., Mao, G., & Ma, Y. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117960 · Cited by 11

The intratumoral microbiota heterogenicity is related to the prognosis and tumorigenesis of cervical cancer

Guo, Y., Xiao, Y., Zhang, C., Wang, Y., Cao, G., Tse, K. Y., Han, Z., Li, F., & Zhi, Y. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1574511 · Cited by 16

Epidemiological approaches to evaluate clinical unmasking of HPV ‐associated cervical lesions in the HPV vaccination era

Tota, J. E., Shing, J. Z., Roberts, J. N., Anderson, E. M., Saah, A. J., Harari, A., Franco, E. L., Kohn, M. A., & Kjær, S. K. (2025) · International Journal of Cancer · doi:10.1002/ijc.70119 · Cited by 10

Optimizing Cervical Cancer Screening by Age at Vaccination for Human Papillomavirus: Health and Resource Implications

Pedersen, K., Silvestre, J. D., Sy, S., Portnoy, A., Castle, P. E., Kim, J. J., & Burger, E. A. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-03192 · Cited by 11

Lactobacillus-rich cervicovaginal microbiome associated with lower BV, HPV, and cytology outcomes in women

Sekyere, J. O., Trama, J. P., Adelson, M. E., Trikannad, C., DiBlasi, D., Schuster, R., Yang, J., & Mordechai, E. (2025) · iScience · doi:10.1016/j.isci.2025.113473 · Cited by 12

Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9–14 years: A randomized and open-label clinical trial

Xie, F., Du, K., Li, J., Zhong, S., Fan, C., Bi, Z., Zhang, Q., Chen, J., Ma, S., & Zhang, D. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127015 · Cited by 9

HPV Infection in Children and Adolescents—A Comprehensive Review

Tomecka, P., Karwowska, A., Kuźnicki, J., Skinderowicz, K., Wojno, A., Markut, K., Typek, P., Ciesielska, U., Kulbacka, J., & Drąg‐Zalesińska, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072425 · Cited by 8

Lineages and sublineages of high-risk human papillomavirus types associated with cervical cancer and precancer: a systematic review and meta-analysis

van den Borst, E., Bell, M., de Beeck, K. O., Camp, G. V., Keer, S. V., & Vorsters, A. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf118 · Cited by 10

Cationic nanogel–based nasal therapeutic HPV vaccine prevents the development of cervical cancer

Nakahashi-Ouchida, R., Mori, H., Yuki, Y., Machita, T., Katakai, Y., Umemoto, S., Uchida, Y., Yamanoue, T., Sawada, S., Ishige, K., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ado8840 · Cited by 11

Natural History of High-Risk Human Papillomavirus in Kenyan and South African Women: Implications for Vaccination Campaigns and Cervical Cancer Screening Programs

Happel, A., Budiawan, E., Onono, M. A., Innes, S., Palanee‐Phillips, T., Heuvel, J., Rakiep, A., Kellow-Webb, S., Ongere, J. A., Wakhungu, I., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae690 · Cited by 7

Challenges and Opportunities for Global Cervical Cancer Elimination: How Can We Build a Model for Other Cancers?

Adebamowo, C., Rossi, P. G., & Castle, P. E. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473702 · Cited by 13

Human papillomavirus 16 mitigates Sneathia vaginalis -induced damage to cervical keratinocytes

Bridy, P. V., Cruz, J. C., Covington, J. L., Islam, T. I., Hadley, C. E., Tran, K., Fry, R., Sheffield, B. A., Serrano, M. G., Buck, G. A., et al. (2025) · mSphere · doi:10.1128/msphere.00152-25 · Cited by 7

Harnessing the Power of Microbiota: How Do Key Lactobacillus Species Aid in Clearing High-Risk Human Papilloma Virus Infection and Promoting the Regression of Cervical Dysplasia?

Kęczkowska, E., Wrotyńska-Barczyńska, J., Bałabas, A., Piątkowska, M., Dąbrowska, M., Czarnowski, P., Hennig, E. E., Brązert, M., Olcha, P., Ciebiera, M., et al. (2025) · Biology · doi:10.3390/biology14081081 · Cited by 7

Prevalence and genotype distribution of HPV infection among women in Chengdu from 2019 to 2024: a retrospective single-center study

Zhou, X., Ma, J., He, L., & Li, H. (2025) · Infectious Agents and Cancer · doi:10.1186/s13027-025-00698-4 · Cited by 7

Genotype and age shape the risk of persistent high-risk human papillomavirus infections

Numminen, E., Leino, A., Qiang, K., Veronika, F., Seiskari, T., Paloniemi, M., Kholová, I., Kares, S., & Louvanto, K. (2026) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2026.02.038 · Cited by 7

Opportunities to advance cervical cancer prevention and care

Brooke, G., Wendel, S. O., Banerjee, A., & Wallace, N. A. (2024) · Tumour Virus Research · doi:10.1016/j.tvr.2024.200292 · Cited by 8

Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings

Man, I., Georges, D., Basu, P. S., & Baussano, I. (2024) · JNCI Monographs · doi:10.1093/jncimonographs/lgae035 · Cited by 7

Association Between High-Risk Human Papillomavirus Infection and Cervical Cytology in Health Check-Up Women — 23 PLADs, China, 2023

Gao, D., Zhao, G., Wang, X., Juan, J., Shi, Y., Xu, T., Wang, Y., Wang, L., & Zhang, X. (2025) · China CDC Weekly · doi:10.46234/ccdcw2025.053 · Cited by 7

Long‐term human papillomavirus genotype‐specific risk of cervical high‐grade intraepithelial lesion and cancer—By age group and triage cytology

Vahteristo, M., Heinävaara, S. H., Dillner, J., Kalliala, I. E. J., Nieminen, P., Sarkeala, T. M., & Leinonen, M. K. (2025) · International Journal of Cancer · doi:10.1002/ijc.70123 · Cited by 6

Population impact of South Africa's human papillomavirus (HPV) vaccination programme on HPV prevalence in adolescent girls with and without HIV: a repeat cross-sectional study

Machalek, D. A., Nyemba, D. C., Travill, D., Petoumenos, K., Mbulawa, Z. Z. A., Naidoo, I., Motshwane, F. M. M., Bamford, L., Rees, H., Kaldor, J. M., et al. (2026) · The Lancet Global Health · doi:10.1016/s2214-109x(25)00525-x · Cited by 6

Prevalence of non-vaccine high-risk HPV cervical infections in vaccinated women: a systematic review and meta-analysis

do Nascimento, G. R., Santos, A. C. D. S., Silva, N. N. T., Guimarães, N. S., Lima, A. A., & Coura‐Vital, W. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10520-6 · Cited by 6

Analysis of time trends of prevalence of high-risk HPV infections, high grade cervical precancer and cervical cancer disease in women from Eastern India over 20 years − Pooled analysis from three studies

Bose, S., Mandal, R., Banerjee, D., Vernekar, M., Siddiqi, M., Chakrabarti, J., Sankaranarayanan, R., Lucas, E., Muwonge, R., & Basu, P. S. (2025) · Cancer Epidemiology · doi:10.1016/j.canep.2025.102776 · Cited by 6

Ad‐E6/7‐HR vaccine improves the prophylactic and therapeutic efficacy in HPV‐associated cancers

Zhang, Y., Qiu, K., Ai, J., Xu, M., Wang, B., Alu, A., Ye, C., Huang, X., Zhang, Y. L., Zhou, Y., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70305 · Cited by 6

EUROArray HPV test accuracy for cervical precancer in self- vs. clinician-collected samples using the VALHUDES protocol

van den Borst, E., Broeck, D. V., Sutter, P. D., Donders, G. G. G., Doyen, J., Tjalma, W. A. A., Weyers, S., Arbyn, M., Keer, S. V., & Latsuzbaia, A. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.08.018 · Cited by 6

TGF-β Induces the Secretion of Extracellular Vesicles Enriched with CD39 and CD73 from Cervical Cancer Cells

Molina-Castillo, G., Monroy-García, A., García‐Rocha, R., Weiss‐Steider, B., Montesinos, J. J., Hernández‐Montes, J., Don‐López, C. A., Castro-Manrreza, M. E., Escobar, M. L., & Mora‐García, M. D. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062413 · Cited by 5

Human papillomavirus (HPV) as the main cause of cervical and other related cancers: a review

Moosa-Battey, R., Masuku, P., & Mayimele, N. N. (2025) · SA pharmaceutical journal. · doi:10.36303/sapj.1164 · Cited by 5

Emerging Therapeutic Strategies for HPV-Related Cancers: From Gene Editing to Precision Oncology

Çakır, M. O., Kayhan, G., Yilmaz, B., Özdoğan, M., & Ashrafi, G. H. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090759 · Cited by 8

Temporal changes in prevalence and geographical distribution of human papillomavirus infection in mainland China: a systematic review and analysis of 1.07 million females from 2010 to 2021

Chen, Q., Wang, S., Lin, Q., & Zhang, G. (2025) · BMC Public Health · doi:10.1186/s12889-025-24323-6 · Cited by 5

A Field‐Deployable RotEx‐LAMP‐LFA Platform for Molecular Triage of HPV‐Driven Oncogenesis

Gao, Y., Wen, Q., Qiao, S., Deng, L., Li, K., Shao, Z., Liu, X., Zhu, T., Zhang, C., Han, D., et al. (2025) · Advanced Science · doi:10.1002/advs.202509468 · Cited by 5

Prevalence and genotypic characterization of human papillomavirus in Iraqi women: a retrospective study of 2,193 cases

Tahir, M., Mohammed, D., & Sadiq, C. H. (2025) · Virology Journal · doi:10.1186/s12985-025-03021-0 · Cited by 5

Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2+ from childhood vaccinated women: The Trial23 cohort study

Nonboe, M. H., Napolitano, G. M., Schroll, J. B., Andersen, B. S., Christiansen, S., Frandsen, A. P., Pedersen, H., Lynge, E., Bonde, J. H., & Høgdall, E. V. S. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.128142 · Cited by 5

Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis

Rumgay, H., Georges, D., Huang, Y., Hirabayashi, M., Shah, R., de Martel, C., Park, J. Y., Soerjomataram, I., & Clifford, G. M. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00307-4 · Cited by 5

Accuracy of Liferiver HarmoniaHPV and VenusHPV Assays on Urine and Vaginal Self‐Samples

Latsuzbaia, A., Keer, S. V., Broeck, D. V., Weyers, S., Donders, G. G. G., Sutter, P. D., Tjalma, W. A. A., Doyen, J., Vorsters, A., & Arbyn, M. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70273 · Cited by 5

The challenging approach to the management of male partners of HPV-positive women

Bornstein, J., Vieira‐Baptista, P., Stockdale, C. K., Preti, M., Joura, E. A., & Schejter, E. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2515753 · Cited by 5

Prediction of high-grade cervical precancerous abnormalities: The role of personal factors, vaginal microflora, sexually transmitted infections, and high-risk human papillomavirus

Plisko, O., Žodžika, J., Jermakova, I., Pčolkina, K., Prusakevica, A., Liepniece‐Karele, I., Zarina, M., Storoženko, J., & Rezeberga, D. (2024) · PLoS ONE · doi:10.1371/journal.pone.0313004 · Cited by 4

Developing, Validating, and Testing Non-vaccine–Preventable Human Papillomavirus to Control for Differences in Sexual Behavior When Evaluating HPV Vaccination

Dema, E., Shing, J. Z., Checchi, M., Beddows, S. A., Liu, D., Sierra, M. S., Haas, C. B., Soldan, K., Field, N. M., Kreimer, A. R., et al. (2025) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-24-1775 · Cited by 4

Declaration on cervical cancer elimination: literature review and perspectives from early-career clinicians

Kacperczyk-Bartnik, J. P., Hajj, H. E., Tóth, I., Bizzarri, N., Tóth, R., Razumova, Z., Zwimpfer, T. A., Taumberger, N., Bilir, E., Strojna, A. N., et al. (2025) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.101902 · Cited by 7

Organizational barriers in HPV vaccination uptake: A cross-sectional study among health sciences students

Palena, G., Stilo, I., Sorrentino, M., Fiorilla, C., & Palladino, R. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326694 · Cited by 4

Multiple high-risk human papillomavirus infections exacerbate cervical lesion risk: epidemiological evidence from suining, Sichuan

Jing, Y., Chen, J., Lin, F., Huang, X., Liu, Y., Zhao, M., Ye, C., Zhao, L., Liu, X., & Yang, J. (2025) · Virology Journal · doi:10.1186/s12985-025-02904-6 · Cited by 4

The High Prevalence of Oncogenic HPV Genotypes Targeted by the Nonavalent HPV Vaccine in HIV-Infected Women Urgently Reinforces the Need for Prophylactic Vaccination in Key Female Populations Living in Gabon

Mboumba-Mboumba, M., Mouinga‐Ondémé, A., Moussavou-Boundzanga, P., Engone-Ondo, J. D., Mourimarodi, R. M., Diane, A., Ayoumi, C. O., Bélec, L., Bouassa, R. M., & Mfouo-Tynga, I. S. (2025) · Diseases · doi:10.3390/diseases13080260 · Cited by 4

Temporal Trends in Cervical Human Papillomavirus Prevalence Among Females in Xiamen, China (2016-2023): Cross-Sectional Study

Chen, Z., Lin, E., Chen, M., Wang, S., Lin, Q., Chen, Q., Xue, H., & Zhang, G. (2025) · JMIR Public Health and Surveillance · doi:10.2196/70507 · Cited by 4

Barriers to HPV vaccine introduction and revitalization in sub-Saharan francophone African countries – A qualitative descriptive study

Waheed, D.-E.-N., Bolio, A., Burdier, F. R., Guillaume, D., Biey, J., Ndiaye, C., Karafillakis, E., Kouassi, K. S., Vorsters, A., & Morgan, C. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.128030 · Cited by 4

Exceeding expectations: factors contributing to the potency of human papillomavirus vaccines

Schiller, J. T., Kines, R. C., Day, P. M., Çuburu, N., Kreimer, A. R., & Lowy, D. R. (2026) · The Lancet Microbe · doi:10.1016/j.lanmic.2026.101401 · Cited by 4

The rational design of cervical cancer prevention strategies

Schiffman, M., & de Sanjose, S. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01547-2 · Cited by 4

Human Papillomavirus Primary Screening and Collaboration in Quality Assurance Work between Laboratories

Edvardsson, H., & Dillner, J. (2025) · Acta Cytologica · doi:10.1159/000544988 · Cited by 4

Immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18–26 years: three-year follow-up data from a randomised clinical trial

Zhong, G., Bi, Z., Chu, K., Zhang, L., Chen, L., Zhu, K., Quan, J., Nie, C., Chen, Q., Qiu, L., et al. (2025) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2025.101671 · Cited by 4

Risk‐Based Triage Strategy by Extended HPV Genotyping for Women With LSIL Cytology: A Real‐World Study

Ye, C., Liu, Y., Huang, H., Chen, R., Li, Y., Zhang, X., Fu, Y., Feng, L., & Li, X. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70404 · Cited by 3

Changes in the Epidemiology of High‐Risk HPV Genital Tract Infections Among Women in Shanghai: A Pre‐ and Post‐COVID‐19 Pandemic Analysis (2013–2024)

Yu, J., Ju, Y., Kim, D., Qian, A., Du, B., Liu, N., & Wei, Z. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70424 · Cited by 3

High-risk human papillomavirus (hr-HPV) prevalence and abnormal cervical cytology in rural high-altitude communities: a population-based cross-sectional study in the Southern Tibetan Plateau, China (2023–2024)

Chen, M., Lhamo, Y., Chödrön, K., & Chen, L. (2025) · Virology Journal · doi:10.1186/s12985-025-02909-1 · Cited by 3

HPV Integration: Moving From Carcinogenesis Mechanisms to Clinical Applications

Lai, S., Liu, H., Chu, T., & Cao, C. (2025) · Med Research · doi:10.1002/mdr2.70026 · Cited by 3

Clinical Significance of Tumor Infiltrating T-Helper and Regulatory Cells in Bulgarian Cervical Cancer Patients

Yordanov, A. D., Damyanova, P., Vasileva‐Slaveva, M., Karakadieva, K., Kostov, S. G., & Shivarov, V. S. (2025) · Biomedicines · doi:10.3390/biomedicines13092206 · Cited by 3

Genotype distribution and molecular characterization of HPV in the Peruvian amazon: insights into prevalence, lineage diversity, and viral integration

Solis-Ponce, L., Stosic, M. S., Curicó, G., Espetia, S., Sanchez-Grandez, H., Hassan, S. S., Basiletti, J. A., Søreng, K., Acuña, M., Huarca, L., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-18455-3 · Cited by 3

The role of extrachromosomal DNA in tumorigenesis and progression

Ma, X., Yu, X., Wu, C., & Song, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1665024 · Cited by 4

Association between female HPV infection, inflammatory markers and depression: a cross-sectional and mediation analysis

Zhang, Y., Ma, S., & He, Z. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11590-2 · Cited by 4

Human Papillomavirus (HPV) and Infertility: A Cross‐Sectional Study Exploring Its Prevalence and Effects in Iranian Couples

Aliabadi, N., Hosseini, M., Doustfatemeh, S., Marandi, N. H., Joukar, M., Faramarzi, H., Asmarian, N., & Namazi, N. (2025) · Health Science Reports · doi:10.1002/hsr2.71624 · Cited by 3

Vaccine-preventable HPV burden and cervical abnormalities in women during 2022–2024 Octobre Rose campaigns in Libreville

Mabika-Obanda, A. K. F., Ledaga, N. A., Ngou-Milama, K. M. M., Obame, V. Z., Emane, A. K. A., Sanon, A., Ndong-Ella, C., Loemba, H., Bélec, L., Ngou, J. P. N. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67777-3 · Cited by 3

Diagnostic performance and clinical utility of p16 immunostaining in a population-based HPV DNA screening program

Sardinha, T. G., Vale, D. B., Discacciati, M. G., Triglia, R. D. M., Coelho, R. M. R. D. S., Jundurian, M., Campos, C. S., Zeferino, L. C., & Teixeira, J. C. (2025) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.104451 · Cited by 3

Molecular Pathogenesis of HPV16‐Associated Cervical Cancer: From Viral Entry to Therapeutic Interventions

Kumar, S., Yadav, P., Maurya, A., Yadav, S. C., & Prasad, T. (2026) · ChemistrySelect · doi:10.1002/slct.202505590 · Cited by 4

Type‐ and age‐specific natural history of high‐risk human papillomavirus infections in healthy women: A prospective cohort study in China

Quan, J., Chen, Q., Lan, L., Zhang, B., Hu, Y., Zhao, F., Wang, X., Wang, X., Huang, J., Zhong, G., et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70337 · Cited by 3

HPV genotype prevalence in low- and high-vaccine coverage, USA populations: Data from real-world cervical cancer screening using the Onclarity HPV assay

Morel, D. R., Parvu, V., Andrews, J., Stephenson, P., Bull, J., Woodward, A., & Vaughan, L. M. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.02.016 · Cited by 3

Trends and patterns of human papillomavirus infection among 33.7 million women in mainland China from 2015 to 2025: A nationwide observational study

Li, X., Sun, Y., Lun, X., Liang, Y., Jin, R., & Liu, J. (2026) · Journal of Infection · doi:10.1016/j.jinf.2026.106732 · Cited by 3

Effectiveness, immunogenicity and safety of human papillomavirus vaccination in non-HIV immunocompromised individuals: a systematic review

Kapp, P., Siemens, W., Gorenflo, L., Schulz, H., Chi, Y., Röbl-Mathieu, M., Askar, M., Brotons, M., Andersen, P. H., Konopnicki, D., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103865 · Cited by 3

Oncogenic infections: targets highly amenable to cancer prevention

Alberts, C. J., Georges, D., Franceschi, S., Baussano, I., Park, J. Y., Rumgay, H., Basu, P. S., & Clifford, G. M. (2025) · JNCI Monographs · doi:10.1093/jncimonographs/lgaf040 · Cited by 3

Genotypic analysis of human papillomavirus in cervical exfoliated cells from women in Zigong

Ma, X., Wu, C., Wu, T., Yu, X., & Song, L. (2025) · Virology Journal · doi:10.1186/s12985-025-02652-7 · Cited by 3

Study on the clinical characteristics, persistent infection capability, and viral load of human papillomavirus type 82 single infection

Chen, Z., Cheng, Q., Zhang, X., Tao, F., Li, N., Liu, G., Mu, X., Zhang, M., Dong, Z., & Li, Q. (2025) · Virology Journal · doi:10.1186/s12985-025-02688-9 · Cited by 3

Study on the detection rate, genetic polymorphism, viral load, persistent infection capacity, and pathogenicity of human papillomavirus type 33

Li, Q., Cheng, Q., Tian, D., An, Z., Li, L., Yang, F., Zhang, M., Liu, G., Peixin, A., Yang, Y. F., et al. (2025) · Virology Journal · doi:10.1186/s12985-025-02752-4 · Cited by 3

Minimally invasive diagnosis of precancerous cervical lesions using single-cell peripheral immune atlas

Xu, J., Ji, Q., Kong, Q., Lv, L., Bo, Z., Huang, X., Chen, Z., Xu, P., Li, X., Yin, W., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102149 · Cited by 3

The Predictive Impact of HPV Genotypes, Tumor Suppressors and Local Immune Response in the Regression of Cervical Intraepithelial Neoplasia 2-3: A Prospective Population-Based Cohort Study

Sustova, P., Engesæter, B. Ø., Øvestad, I. T., Gudlaugsson, E. G., Ghiasvand, R., Skaland, I., Baak, J. P. A., Tropé, A., Janssen, E. A. M., & Munk, A. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115205 · Cited by 3

Prevalence and distribution of human papillomavirus in genital warts in Can Tho City, Vietnam: a cross-sectional study

Ngân, L. T. K., Ba, H. V., Kim, D. H. T., Khoa, D. T. D., Hùng, N. T., Tram, P. T. B., Trang, N. T. T., Khiêm, N. H., Thảo, P. T., Hien, T. D., et al. (2025) · Infectious Agents and Cancer · doi:10.1186/s13027-025-00685-9 · Cited by 3

China adds HPV shot as first new immunisation programme vaccine in 17 years

Murphy, F. (2025) · BMJ · doi:10.1136/bmj.r1985 · Cited by 3

Genital infections in high-risk human papillomavirus positive Paraguayan women aged 30–64 with and without cervical lesions

Arévalos, A., Valenzuela, A., Mongelós, P., Barrios, H., Rodríguez-Riveros, M. I., Báez, R., Centurión, C., Vester, J. M., Soilán, A. M., Ortega, M., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312947 · Cited by 3

Study on the clinical characteristics, persistent infection capability and viral load of human papillomavirus type 26 single infection

Chen, Z., Li, X., Tian, D., Liu, J. J., Bai, X., Feng, T., Chen, S., Chen, L., & Li, Q. (2024) · Virology Journal · doi:10.1186/s12985-024-02582-w · Cited by 3

Discontinuation of cervical cancer screening for HPV ‐vaccinated women?

Bonde, J. H., & Hammer, A. (2024) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14978 · Cited by 3

Causal Attribution of Human Papillomavirus Types to Invasive Cervical Cancer Worldwide: A Systematic Analysis of the Global LiteraturePreprint

Wei, F., Georges, D., Man, I., Baussano, I., & Clifford, G. M. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4692586 · Cited by 4

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

de Sanjose, S., Quint, W. G., Alemany, L., Geraets, D. T., Klaustermeier, J. E., Lloveras, B., Tous, S., Felix, A., Bravo, L. E., Shin, H.-R., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70230-8 · Cited by 2,728

HPV genotypes: implications for worldwide cervical cancer screening and vaccination

de Sanjosé, S. (2010)

Identification of HPV genotypes causing cervical precancer using tissue‐based genotyping

Venetianer, R., Clarke, M. A., van der Marel, J., Tota, J. E., SCHIFFMAN, M. H., Dunn, S. T., Walker, J. L., Zuna, R. E., Quint, W. G. V., & Wentzensen, N. (2020) · International Journal of Cancer · doi:10.1002/ijc.32919 · Cited by 23

Ranking the attribution of high-risk genotypes among women with cervical precancers and cancers: a cross-sectional study in Ningbo, China

Chen, S., Hu, S., Yin, J., Yu, W., Zhang, X., Deng, X., Ding, H., Zhang, J., Song, Y. Y., Wang, Q., et al. (2024) · Infectious Agents and Cancer · doi:10.1186/s13027-024-00598-z · Cited by 1